Core Viewpoint - Hutchison China MediTech Limited (00013) experienced a significant decline of over 13% in its stock price, closing at HKD 24.36 with a trading volume of HKD 401 million following the release of its interim results [1] Financial Performance - The company reported a revenue of USD 278 million for the period, representing a year-on-year decrease of 9.2%, primarily due to a decline in sales in the mainland market [1] - Despite the revenue drop, the income from fruquintinib remained stable, offsetting some of the negative impacts [1] - The net profit surged to USD 455 million, marking a 16.6-fold increase, with earnings per share at USD 0.53 [1] - The company did not declare any dividends for this period [1] Strategic Moves - In January, the company announced the sale of its 45% stake in Shanghai Hutchison Pharmaceuticals for HKD 608 million [1] - Citigroup noted that this divestment would further strengthen the company's capital and debt structure, allowing it to focus resources on core business areas [1] - Guotai Junan stated that the transaction would help the company concentrate on discovering, developing, and commercializing innovative therapies for cancer and immune diseases [1]
和黄医药早盘跌超13% 中期营收同比下滑9.2% 出售合资股权带动纯利增超16倍